静脉-静脉体外膜氧合患者的胸部出血并发症
该回顾性分析纳入418例接受静脉-静脉体外膜氧合(vv-ECMO)的患者,23.2%发生相关出血,胸部出血占41.2%(总体9.6%),为最常见出血类型。胸部出血患者院内死亡率52.5%,显著高于无出血患者的32.7%(p=0.013),且60%需外科手术干预。
要点
- vv-ECMO患者胸部出血发生率为9.6%,是最常见的出血并发症。
- 胸部出血患者院内死亡率为52.5%,显著高于无出血者的32.7%。
- 60%的胸部出血患者需外科手术,其中45.8%需再次手术止血。
核心结论
- 胸部出血并发症在vv-ECMO治疗中发生率为9.6%,是最常见的出血并发症,且与更高的院内死亡率相关。
主要发现
- 23.2%(n=97)的患者记录到相关出血,其中胸部出血40例(41.2%),弥漫性出血21.6%,脑出血14.4%,胃肠道出血6.2%,插管部位出血6.2%。
- 胸部出血原因包括自发性(40%)、术后(37.5%)、干预后(20%)及创伤后(2.5%)。
- 胸部出血患者中60%(n=24)接受外科手术,45.8%因出血需再次手术。
- 胸部出血患者平均ECMO持续时间18.6±16.8天(p=0.035)和住院时间58±50天(p=0.002)显著长于无出血患者。
- 胸部出血患者院内死亡率为52.5%,显著高于无出血并发症患者的32.7%(p=0.013)。
临床怎么用
- vv-ECMO应仅在具备胸外科经验的中心开展,以应对高风险的胸部出血并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with respiratory failure are treated more frequently with venovenous extracorporeal membrane oxygenation (vv-ECMO). These patients are at risk for bleeding due to complex multifactorial coagulation disorders resulting from the extracorporeal circulation. METHODS: A retrospective analysis was conducted of prospectively collected data on all patients requiring vv-ECMO between December 2010 and December 2016. End points were the incidence, consequence, and in-hospital mortality of patients with thoracic bleeding complications. RESULTS: The study included 418 patients (aged 50 ± 16.5 years) requiring vv-ECMO. In 23.2% (n = 97) of patients, relevant hemorrhage was documented. Thoracic bleeding developed in 40 patients (41.2%), followed by diffuse (21.6%), cerebral (14.4%), gastrointestinal (6.2%), cannulation site (6.2%), and other bleeding locations. Thoracic bleeding complications occurred spontaneously (40%), postoperatively (37.5%), after interventions (20%), and after trauma (2.5%). A thoracic operation was performed in 60% (n = 24) of these patients, and a repeated operation due to bleeding was necessary in 45.8%. Mean ECMO duration (18.6 ± 16.8 days; p = 0.035) and hospital length of stay (58 ± 50 days; p = 0.002) were significantly longer than that in patients without bleeding. In-hospital mortality was significantly higher in patients with thoracic bleeding complications (52.5%) than in patients without bleeding complications (32.7%; p = 0.013). CONCLUSIONS: Thoracic bleeding complications were observed in 9.6% of patients and represented the most frequent bleeding complication during vv-ECMO treatment. Almost 60% of patients required surgical revision, and nearly half of these patients underwent a repeated operation. Because mortality is high in these patients, vv-ECMO should be performed in only centers experienced with thoracic surgery.
引用
- Ried M, Sommerauer L, Lubnow M, et al. Thoracic Bleeding Complications in Patients With Venovenous Extracorporeal Membrane Oxygenation. Ann Thorac Surg. 2018. PMID: 30193999. doi:10.1016/j.athoracsur.2018.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。